Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases
Authors:
- Javier Dı́az-NidoJavier Dı́az-Nido
- Francisco WandosellFrancisco Wandosell
- Jesús AvilaJAJesús Avila
Abstract
No abstract availableKeywords
This publication has 107 references indexed in Scilit:
- A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) disease in transgenic miceJournal of Molecular Biology, 2000
- Lithium protects cultured neurons against β‐amyloid‐induced neurodegenerationFEBS Letters, 1999
- Polymerization of tau peptides into fibrillar structures. The effect of FTDP‐17 mutationsFEBS Letters, 1999
- Polymerization of τ into Filaments in the Presence of Heparin: The Minimal Sequence Required for τ ‐ τ InteractionJournal of Neurochemistry, 1996
- Role of Proteoglycans in Neural Development, Regeneration, and the Aging BrainJournal of Neurochemistry, 1996
- Proteoglycan-mediated Inhibition of Aβ ProteolysisJournal of Biological Chemistry, 1995
- PROTEOGLYCANS: STRUCTURES AND INTERACTIONSAnnual Review of Biochemistry, 1991
- A modified form of microtubule-associated tau protein is the main component of paired helical filamentsBiochemical and Biophysical Research Communications, 1988
- Self assembly of microtubule associated protein tau into filaments resembling those found in alzheimer diseaseBiochemical and Biophysical Research Communications, 1986
- Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in SpleenJournal of General Virology, 1984